Thomas J. Herzfeld Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21	Closed	-$3.72K	–	163
2023 Q3	$3.72K	Hold	21	–	–	﹤0.01%	283
2023 Q2	$3.99K	Hold	21	–	–	﹤0.01%	279
2023 Q1	$4.21K	Hold	21	–	–	﹤0.01%	254
2022 Q4	$4.99K	Buy	21 +7	+50%	+$1.49K	﹤0.01%	234
2022 Q3	$3K	Buy	+14	New	+$2.67K	﹤0.01%	239
2016 Q1	–	Sell	-50	Closed	-$5K	–	333
2015 Q4	$5K	Hold	50	–	–	﹤0.01%	313
2015 Q3	$4K	Buy	+50	New	+$5.55K	﹤0.01%	315

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Thomas J. Herzfeld Advisors's ALNY Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 21 shares — an estimated $3.72K sold.

Thomas J. Herzfeld Advisors first reported a position in ALNY in Q3 2015 and held it in 7 quarters. The position peaked at $5K in Q4 2015. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 21 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $3.72K.
Thomas J. Herzfeld Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 7 quarters.
Thomas J. Herzfeld Advisors's Alnylam Pharmaceuticals position peaked at $5K in Q4 2015.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.